Tumor suppressor loci in bladder cancer

Frontiers in Bioscience

Volumn 12, Issue 6, 2007, Pages 2233-2251

  Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bladder Cancer; Neoplasia; Review; Tumour suppressor gene; Urinary tract

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

BLADDER TUMOR; CHROMOSOME 9; CLASSIFICATION; DNA METHYLATION; GENE SILENCING; GENETICS; HETEROZYGOSITY LOSS; HUMAN; METABOLISM; MUTATION; REVIEW; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, HUMAN, PAIR 9; DNA METHYLATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 36048960039     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2226     Document Type: Article

References (164)

1. Cancer Research UK. Bladder Cancer-UK. Cancer Stats. (2002)
2. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. Cancer statistics, 2003. CA Cancer J. Clin., 53, 5-26 (2003) (Pubitemid 36163619)
3. Silverman, D.T., Hartge, P., Morrison, A.S. and Devesa, S.S. Epidemiology of bladder cancer. Hematol. Oncol. Clin. North Am., 6, 1-30 (1992)
4. Kinzler, K.W. and Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature, 386, 761, 763 (1997)
5. Knudson, A.G. Timeline - Two genetic hits (more or less) to cancer. Nature Reviews Cancer, 1, 157-170 (2001)
6. Santarosa, M. and Ashworth, A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim. Biophys. Acta, 1654, 105 (2004)
7. Sandberg, A.A. Cytogenetics and molecular genetics of bladder cancer: a personal view. Am. J. Med. Genet., 115, 173-82. (2002) (Pubitemid 35265507)
8. Kallioniemi, A., Kallioniemi, O.-P., Citro, G., Sauter, G., DeVries, S., Kerschmann, R., Caroll, P. and Waldman, F. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridisation. Genes Chromosomes and Cancer, 12, 213-219 (1995)
9. Richter, J., Beffa, L., Wagner, U., Schraml, P., Gasser, T.C., Moch, H., Mihatsch, M.J. and Sauter, G. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am. J. Pathol., 153, 1615-21 (1998) (Pubitemid 28509919)
10. Richter, J., Jiang, F., Gorog, J.P., Sartorius, G., Egenter, C., Gasser, T.C., Moch, H., Mihatsch, M.J. and Sauter, G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res., 57, 2860-4 (1997) (Pubitemid 27315028)
11. Simon, R., Bürger, H., Brinkschmidt, C., Böcker, W., Hertle, L. and Terpe, H.J. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J. Pathol., 185, 345-51 (1998) (Pubitemid 28355966)
12. Simon, R., Burger, H., Semjonow, A., Hertle, L., Terpe, H.J. and Bocker, W. Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol, 17, 1025-9 (2000)
13. Hurst, C.D., Fiegler, H., Carr, P., Williams, S., Carter, N.P. and Knowles, M.A. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene, 23, 2250-2263 (2004) (Pubitemid 38482541)
14. Veltman, J.A., Fridlyand, J., Pejavar, S., Olshen, A.B., Korkola, J.E., DeVries, S., Carroll, P., Kuo, W.L., Pinkel, D., Albertson, D. et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res., 63, 2872-80 (2003) (Pubitemid 36667159)
15. Blaveri, E., Brewer, J.L., Roydasgupta, R., Fridlyand, J., DeVries, S., Koppie, T., Pejavar, S., Mehta, K., Carroll, P., Simko, J.P. et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res, 11, 7012 (2005)
16. Jones, P.A. DNA methylation and cancer. Oncogene, 21, 5358-60. (2002) (Pubitemid 34983472)
17. UICC (1978) TNM classification of malignant tumors, bladder. In. 3 ed. Union Internationale Contre le Cancer, Geneva, pp. 113-117.
18. WHO Histological typing of urinary bladder tumours. International Histological Classification of Tumours, 10 (1973)
19. WHO (2004) WHO Classification Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon.
20. Fadl-Elmula, I., Gorunova, L., Mandahl, N., Elfving, P., Lundgren, R., Mitelman, F. and Heim, S. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer, 29, 256-65. (2000)
21. Tsai, Y.C., Nichols, P.W., Hiti, A.L., Williams, Z., Skinner, D.G. and Jones, P.A. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res., 50, 44-47 (1990) (Pubitemid 20029991)
22. Shaw, M.E. and Knowles, M.A. Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes and Cancer, 13, 1-8 (1995)
23. Zhao, J., Richter, J., Wagner, U., Roth, B., Schraml, P., Zellweger, T., Ackermann, D., Schmid, U., Moch, H., Mihatsch, M.J. et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res., 59, 4658-61 (1999) (Pubitemid 29428972)
24. Takahashi, T., Habuchi, T., Kakehi, Y., Mitsumori, K., Akao, T., Terachi, T. and Yoshida, O. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res., 58, 5835-41 (1998) (Pubitemid 29006426)
25. Cairns, P., Shaw, M.E. and Knowles, M.A. Initiation of bladder cancer may involve deletion of a tumoursuppressor gene on chromosome 9. Oncogene, 8, 1083-1085 (1993) (Pubitemid 23087444)
26. Linnenbach, A.J., Pressler, L.B., Seng, B.A., Simmel, B.S., Tomaszewski, J.E. and Malkowicz, S.B. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Human Mol. Gen., 2, 1407-1411 (1993) (Pubitemid 23271185)
27. Simoneau, M., Aboulkassim, T.O., LaRue, H., Rousseau, F. and Fradet, Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene, 18, 157-63 (1999) (Pubitemid 29060589)
28. van Tilborg, A.A., de Vries, A., de Bont, M., Groenfeld, L.E., van der Kwast, T.H. and Zwarthoff, E.C. Molecular evolution of multiple recurrent cancers of the bladder. Hum. Mol. Genet., 9, 2973-80. (2000) (Pubitemid 32000770)
29. Louhelainen, J., Wijkstrom, H. and Hemminki, K. Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer. Eur. J. Cancer, 36, 1441-51 (2000) (Pubitemid 30421150)
30. Hartmann, A., Moser, K., Kriegmair, M., Hofstetter, A., Hofstaedter, F. and Knuechel, R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am. J. Pathol., 154, 721-7 (1999) (Pubitemid 29122590)
31. Aboulkassim, T.O., LaRue, H., Lemieux, P., Rousseau, F. and Fradet, Y. Alteration of the PATCHED locus in superficial bladder cancer. Oncogene, 22, 2967-71 (2003) (Pubitemid 36648924)
32. Habuchi, T., Luscombe, M., Elder, P.A. and Knowles, M.A. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics, 48, 277-88 (1998) (Pubitemid 28180727)
33. Czerniak, B., Chaturvedi, V., Li, L., Hodges, S., Johnston, D., Roy, J.Y., Luthra, R., Logothetis, C., Von Eschenbach, A.C., Grossman, H.B. et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene, 18, 1185-96 (1999) (Pubitemid 29085991)
34. Wada, T., Berggren, P., Steineck, G., Adolfsson, J., Wijkstrom, H., Norming, U., Hansson, J., Hemminki, K. and Larsson, P. Bladder neoplasms-regions at chromosome 9 with putative tumour suppressor genes. Scand. J. Urol. Nephrol., 37, 106-11 (2003) (Pubitemid 36535227)
35. Cairns, P., Mao, L., Merlo, A., Lee, D.J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J.E. and Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-7 (1994) (Pubitemid 24259979)
36. Devlin, J., Keen, A.J. and Knowles, M.A. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene, 9, 2757-2760 (1994) (Pubitemid 24254057)
37. Orlow, I., Lacombe, L., Hannon, G.J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V.E., Zhang, Z.-F., Beach, D. and Cordon-Cardo, C. Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst., 87, 1524-1529 (1995)
38. Williamson, M.P., Elder, P.A., Shaw, M.E., Devlin, J. and Knowles, M.A. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet., 4, 1569-1577 (1995)
39. Berggren, P., Kumar, R., Sakano, S., Hemminki, L., Wada, T., Steineck, G., Adolfsson, J., Larsson, P., Norming, U., Wijkstrom, H. et al. Detecting homozygous deletions in the CDKN2A (p16 (INK4a))/ARF (p14 (ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res, 9, 235-42 (2003) (Pubitemid 36109739)
40. McGarvey, T.W., Maruta, Y., Tomaszewski, J.E., Linnenbach, A.J. and Malkowicz, S.B. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene, 17, 1167-72 (1998) (Pubitemid 28444601)
41. Nishiyama, H., Takahashi, T., Kakehi, Y., Habuchi, T. and Knowles, M.A. Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer, 26, 171-5 (1999) (Pubitemid 29416443)
42. Stadler, W.M., Steinberg, G., Yang, X., Hagos, F., Turner, C. and Olopade, O.I. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res, 7, 1676-82. (2001) (Pubitemid 32708635)
43. Adachi, H., Igawa, M., Shiina, H., Urakami, S., Shigeno, K. and Hino, O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J. Urol., 170, 601-4 (2003) (Pubitemid 36870268)
44. Hornigold, N., Devlin, J., Davies, A.M., Aveyard, J.S., Habuchi, T. and Knowles, M.A. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene, 18, 2657-61 (1999) (Pubitemid 29216689)
45. Knowles, M.A., Habuchi, T., Kennedy, W. and Cuthbert-Heavens, D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res., 63, 7652-7656 (2003) (Pubitemid 37466691)
46. Cairns, P., Tokino, K., Eby, Y. and Sidransky, D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res., 54, 1422-1424 (1994) (Pubitemid 24106400)
47. Packenham, J.P., Taylor, J.A., Anna, C.H., White, C.M. and Devereux, T.R. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol. Carcinog., 14, 147-51 (1995)
48. Spruck, C.H., 3rd, Gonzalez-Zulueta, M., Shibata, A., Simoneau, A.R., Lin, M.F., Gonzales, F., Tsai, Y.C. and Jones, P.A. p16 gene in uncultured tumours. Nature, 370, 183-4 (1994)
49. Chang, L.L., Yeh, W.T., Yang, S.Y., Wu, W.J. and Huang, C.H. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J. Urol., 170, 595-600 (2003)
50. Florl, A.R., Franke, K.H., Niederacher, D., Gerharz, C.D., Seifert, H.H. and Schulz, W.A. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab. Invest., 80, 1513-22 (2000)
51. Orlow, I., LaRue, H., Osman, I., Lacombe, L., Moore, L., Rabbani, F., Meyer, F., Fradet, Y. and Cordon-Cardo, C. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am. J. Pathol., 155, 105-13. (1999) (Pubitemid 29318709)
52. Friedrich, M.G., Blind, C., Milde-Langosch, K., Erbersdobler, A., Conrad, S., Loning, T., Hammerer, P. and Huland, H. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur. Urol., 40, 518-24. (2001) (Pubitemid 34289750)
53. Chapman, E.J., Harnden, P., Chambers, P., Johnston, C. and Knowles, M.A. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res, 11, 5740-7 (2005) (Pubitemid 41170298)
54. Van Tilborg, A.A., Hekman, A.C., Vissers, K.J., van der Kwast, T.H. and Zwarthoff, E.C. Loss of heterozygosity on chromosome 9 and loss of chromosome 9 copy number are separate events in the pathogenesis of transitional cell carcinoma of the bladder. Int. J. Cancer, 75, 9-14 (1998) (Pubitemid 28113970)
55. Serrano, M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis, 21, 865-9. (2000) (Pubitemid 30265127)
56. Carnero, A., Hudson, J.D., Price, C.M. and Beach, D.H. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol, 2, 148-55 (2000)
57. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O. and Reznikoff, C. Increased p16 levels correlate with pRB alterations in human urothelial cells. Cancer Res., 55, 493-497 (1995)
58. Benedict, W.F., Lerner, S.P., Zhou, J., Shen, X., Tokunaga, H. and Czerniak, B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene, 18, 1197-203 (1999) (Pubitemid 29085992)
59. Shariat, S.F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G.E., Benedict, W.F. and Lerner, S.P. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol., 22, 1014-24 (2004) (Pubitemid 41095033)
60. Hitchings, A.W., Kumar, M., Jordan, S., Nargund, V., Martin, J. and Berney, D.M. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br. J. Cancer, 91, 552-7 (2004) (Pubitemid 39093578)
61. Simoneau, A.R., Spruck, C.H., 3rd, Gonzalez-Zulueta, M., Gonzalgo, M.L., Chan, M.F., Tsai, Y.C., Dean, M., Steven, K., Horn, T. and Jones, P.A. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res., 56, 5039-43 (1996) (Pubitemid 26374446)
62. Xie, J., Johnson, R.L., Zhang, X., Bare, J.W., Waldman, F.M., Cogen, P.H., Menon, A.G., Warren, R.S., Chen, L.C., Scott, M.P. et al. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res., 57, 2369-72 (1997) (Pubitemid 27255892)
63. Hamed, S., LaRue, H., Hovington, H., Girard, J., Jeannotte, L., Latulippe, E. and Fradet, Y. Accelerated induction of bladder cancer in patched heterozygous mutant mice. Cancer Res., 64, 1938-42 (2004) (Pubitemid 38339437)
64. Habuchi, T., Takahashi, T., Kakinuma, H., Wang, L., Tsuchiya, N., Satoh, S., Akao, T., Sato, K., Ogawa, O., Knowles, M.A. et al. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene, 20, 531-7 (2001) (Pubitemid 32158233)
65. Wright, K.O., Messing, E.M. and Reeder, J.E. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene, 23, 82-90 (2004) (Pubitemid 38142242)
66. Nishiyama, H., Gill, J.H., Pitt, E., Kennedy, W. and Knowles, M.A. Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene, 20, 2956-2964 (2001) (Pubitemid 33027763)
67. Edwards, J., Duncan, P., Going, J.J., Watters, A.D., Grigor, K.M. and Bartlett, J.M. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J. Pathol., 196, 380-5. (2002) (Pubitemid 34262848)
68. Manning, B.D. and Cantley, L.C. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans., 31, 573-8 (2003) (Pubitemid 36750733)
69. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 8, 179-83 (2005) (Pubitemid 41317589)
70. Sidransky, D., von Eschenbach, A., Tsai, Y.C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S.R., Frost, P. et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252, 706-709 (1991) (Pubitemid 21916998)
71. Fujimoto, K., Yamada, Y., Okajima, E., Kakizoe, T., Sasaki, H., Sugimura, T. and Terada, M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52, 1393-1398 (1992)
72. Spruck, C.H., III, Rideout, W.M., III, Olumi, A.F., Ohnesit, P F, Yang, A.S., Tsai, Y.C., Nichols, P.W., Horn, T. et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res., 53, 1162-1166 (1993) (Pubitemid 23087923)
73. Williamson, M.P., Elder, P.A. and Knowles, M.A. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes and Cancer, 9, 108-118 (1994) (Pubitemid 24047466)
74. LaRue, H., Allard, P., Simoneau, M., Normand, C., Pfister, C., Moore, L., Meyer, F., Tetu, B. and Fradet, Y. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis, 21, 101-6 (2000) (Pubitemid 30064150)
75. Sanders, B.M., Jay, M., Draper, G.J. and Roberts, E.M. Non-ocular cancer in relatives of retinoblastoma patients. Br. J. Cancer, 60, 358 (1989)
76. DerKinderen, D.J., Koten, J.W., Nagelkerke, N.J., Tan, K.E., Beemer, F.A. and Den Otter, W. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int. J. Cancer, 41, 499 (1988)
77. Cairns, P., Proctor, A.J. and Knowles, M.A. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene, 6, 2305-2309 (1991) (Pubitemid 21924078)
78. Xu, H.J., Cairns, P., Hu, S.X., Knowles, M.A. and Benedict, W.F. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int. J. Cancer, 53, 781-4 (1993) (Pubitemid 23100121)
79. Sherr, C.J. and McCormick, F. The RB and p53 pathways in cancer. Cancer Cell, 2, 103-12 (2002) (Pubitemid 41039110)
80. Habuchi, T., Takahashi, R., Yamada, H., Ogawa, O., Kakehi, Y., Ogura, K., Hamazaki, S., Toguchida, J., Ishizaki, K., Fujita, J. et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res., 53, 3795-3799 (1993) (Pubitemid 23252045)
81. Esrig, D., Spruck, C.H.d., Nichols, P.W., Chaiwun, B., Steven, K., Groshen, S., Chen, S.C., Skinner, D.G., Jones, P.A. and Cote, R.J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143, 1389-97 (1993) (Pubitemid 24057109)
82. Esrig, D., Elmajian, D., Groshen, S., Freeman, J.A., Stein, J.P., Chen, S.-C., Nichols, P., Skinner, D.G., Jones, P.A. and Cote, R.J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331, 1259-1264 (1994) (Pubitemid 24333190)
83. Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J., Fair, W.R., Herr, H.W. and Reuter, V.E. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152, 388-392 (1994) (Pubitemid 24221226)
84. Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z.-F., Sheinfeld, J., Fair, W.R., Herr, H.W. and Reuter, V.E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85, 53-59 (1993) (Pubitemid 23023225)
85. Sarkis, A.S., Zhang, Z.-F., Cordon-Cardo, C., Melamed, J., Dalbagni, G., Sheinfeld, J., Fair, W.R., Herr, H.W. and Reuter, V.E. p53 nuclear overexpression and disease progression in Ta bladder carcinoma. International Journal of Oncology, 3, 355-360 (1993) (Pubitemid 23273504)
86. Stein, J.P., Ginsberg, D.A., Grossfeld, G.D., Chatterjee, S.J., Esrig, D., Dickinson, M.G., Groshen, S., Taylor, C.R., Jones, P.A., Skinner, D.G. et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90, 1072-9 (1998) (Pubitemid 28350272)
87. Qureshi, K.N., Griffiths, T.R., Robinson, M.C., Marsh, C., Roberts, J.T., Lunec, J., Neal, D.E. and Mellon, J.K. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 51, 1234-40 (2001) (Pubitemid 33116316)
88. Schmitz-Drager, B.J., Goebell, P.J., Ebert, T. and Fradet, Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur. Urol., 38, 691-9;discussion 700 (2000)
89. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W.R., Fuks, Z. and Reuter, V.E. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84, 1251-1256 (1992)
90. Logothetis, C.J., Xu, H.-J., Ro, J.Y., Hu, S.-X., Sahin, A., Ordonez, N. and Benedict, W.F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84, 1256-1261 (1992)
91. Harris, S.L. and Levine, A.J. The p53 pathway: positive and negative feedback loops. Oncogene, 24, 2899-908 (2005) (Pubitemid 40638098)
92. Chatterjee, S.J., Datar, R., Youssefzadeh, D., George, B., Goebell, P.J., Stein, J.P., Young, L., Shi, S.R., Gee, C., Groshen, S. et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol., 22, 1007-13 (2004) (Pubitemid 41095032)
93. Wagner, U., Suess, K., Luginbuhl, T., Schmid, U., Ackermann, D., Zellweger, T., Maurer, R., Alund, G., Knonagel, H., Rist, M. et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J. Pathol., 188, 44-50 (1999) (Pubitemid 29197313)
94. Shiina, H., Igawa, M., Shigeno, K., Terashima, M., Deguchi, M., Yamanaka, M., Ribeiro-Filho, L., Kane, C.J. and Dahiya, R. Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. J. Urol., 168, 2220-6 (2002)
95. Kagan, J., Liu, J., Stein, J.D., Wagner, S.S., Babkowski, R., Grossman, B.H. and Katz, R.L. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene, 16, 909-13 (1998) (Pubitemid 28102594)
96. Cappellen, D., Gil Diez de Medina, S., Chopin, D., Thiery, J.P. and Radvanyi, F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive. Oncogene, 14, 3059-66 (1997)
97. Aveyard, J.S., Skilleter, A., Habuchi, T. and Knowles, M.A. Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer, 80, 904-8 (1999) (Pubitemid 29209858)
98. Yamada, K.M. and Araki, M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci., 114, 2375-82 (2001) (Pubitemid 32684793)
99. Cairns, P., Evron, E., Okami, K., Halachmi, N., Esteller, M., Herman, J.G., Bose, S., Wang, S.I., Parsons, R. and Sidransky, D. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 16, 3215-8 (1998) (Pubitemid 28318794)
100. Liu, J., Babaian, D.C., Liebert, M., Steck, P.A. and Kagan, J. Inactivation of MMAC1 in bladder transitionalcell carcinoma cell lines and specimens. Mol. Carcinog., 29, 143-50 (2000)
101. Wang, D.S., Rieger-Christ, K., Latini, J.M., Moinzadeh, A., Stoffel, J., Pezza, J.A., Saini, K., Libertino, J.A. and Summerhayes, I.C. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int. J. Cancer, 88, 620-5 (2000)
102. Tanaka, M., Koul, D., Davies, M.A., Liebert, M., Steck, P.A. and Grossman, H.B. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene, 19, 5406-12. (2000)
103. Tanaka, M. and Grossman, H.B. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther., 10, 1636-42 (2003) (Pubitemid 37069491)
104. Gildea, J.J., Herlevsen, M., Harding, M.A., Gulding, K.M., Moskaluk, C.A., Frierson, H.F. and Theodorescu, D. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene, 23, 6788-97 (2004) (Pubitemid 39280010)
105. Wu, X., Obata, T., Khan, Q., Highshaw, R.A., De Vere White, R. and Sweeney, C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int, 93, 143-50 (2004) (Pubitemid 38112985)
106. Dulaimi, E., Uzzo, R.G., Greenberg, R.E., Al-Saleem, T. and Cairns, P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res, 10, 1887-93 (2004) (Pubitemid 38375544)
107. Salem, C., Liang, G., Tsai, Y.C., Coulter, J., Knowles, M.A., Feng, A.C., Groshen, S., Nichols, P.W. and Jones, P.A. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res., 60, 2473-6. (2000) (Pubitemid 30262439)
108. Friedrich, M.G., Weisenberger, D.J., Cheng, J.C., Chandrasoma, S., Siegmund, K.D., Gonzalgo, M.L., Toma, M.I., Huland, H., Yoo, C., Tsai, Y.C. et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res, 10, 7457-65 (2004) (Pubitemid 39557507)
109. Ribeiro-Filho, L.A., Franks, J., Sasaki, M., Shiina, H., Li, L.C., Nojima, D., Arap, S., Carroll, P., Enokida, H., Nakagawa, M. et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol. Carcinog., 34, 187-98 (2002) (Pubitemid 34840002)
110. Takle, L.A. and Knowles, M.A. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene, 12, 1083-7 (1996) (Pubitemid 26104451)
111. Stoehr, R., Wissmann, C., Suzuki, H., Knuechel, R., Krieg, R.C., Klopocki, E., Dahl, E., Wild, P., Blaszyk, H., Sauter, G. et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab. Invest., 465-478 (2004) (Pubitemid 41656474)
112. Choi, C., Kim, M.H., Juhng, S.W. and Oh, B.R. Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder. Int. J. Cancer, 86, 501-5 (2000) (Pubitemid 30249729)
113. Wagner, U., Bubendorf, L., Gasser, T.C., Moch, H., Gorog, J.P., Richter, J., Mihatsch, M.J., Waldman, F.M. and Sauter, G. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am. J. Pathol., 151, 753-9 (1997) (Pubitemid 27385607)
114. Ohgaki, K., Iida, A., Ogawa, O., Kubota, Y., Akimoto, M. and Emi, M. Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22. Genes Chromosomes Cancer, 25, 1-5 (1999) (Pubitemid 29183483)
115. Muscheck, M., Sukosd, F., Pesti, T. and Kovacs, G. High density deletion mapping of bladder cancer localizes the putative tumor suppressor gene between loci D8S504 and D8S264 at chromosome 8p23.3. Lab. Invest., 80, 1089-93. (2000) (Pubitemid 30483227)
116. Ishii, H., Baffa, R., Numata, S.I., Murakumo, Y., Rattan, S., Inoue, H., Mori, M., Fidanza, V., Alder, H. and Croce, C.M. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci U S A, 96, 3928-33 (1999) (Pubitemid 29169013)
117. Knowles, M.A., Aveyard, J.S., Taylor, C.F., Harnden, P. and Bass, S. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett., 225, 121-30 (2005) (Pubitemid 40732775)
118. Hamaguchi, M., Meth, J.L., von Klitzing, C., Wei, W., Esposito, D., Rodgers, L., Walsh, T., Welcsh, P., King, M.C. and Wigler, M.H. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A, 99, 13647-52 (2002) (Pubitemid 35215435)
119. Adams, J., Cuthbert-Heavens, D., Bass, S. and Knowles, M.A. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett., 220, 137-44 (2005) (Pubitemid 40568770)
120. Hoffmann, M.J., Florl, A.R., Seifert, H.H. and Schulz, W.A. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int. J. Cancer, 114, 406-13 (2005) (Pubitemid 40279961)
121. Presti, J.C., Jr., Reuter, V.E., Galan, T., Fair, W.R. and Cordon-Cardo, C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res., 51, 5405-9 (1991)
122. Wada, T., Louhelainen, J., Hemminki, K., Adolfsson, J., Wijkstrom, H., Norming, U., Borgstrom, E., Hansson, J. and Steineck, G. li. BJU Int, 87, 876-81 (2001)
123. Li, M., Zhang, Z.F., Reuter, V.E. and Cordon-Cardo, C. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am. J. Pathol., 149, 229-35 (1996) (Pubitemid 26230994)
124. Xu, H.J., Zhou, Y., Seigne, J., Perng, G.S., Mixon, M., Zhang, C., Li, J., Benedict, W.F. and Hu, S.X. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res., 56, 2245-9 (1996) (Pubitemid 26154067)
125. Pagliaro, L.C. Gene therapy for bladder cancer. World J. Urol., 18, 148-51 (2000)
126. Pagliaro, L.C., Keyhani, A., Liu, B., Perrotte, P., Wilson, D. and Dinney, C.P. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol, 21, 456-62 (2003) (Pubitemid 38542722)
127. Li, Y., Pong, R.C., Bergelson, J.M., Hall, M.C., Sagalowsky, A.I., Tseng, C.P., Wang, Z. and Hsieh, J.T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res., 59, 325-30 (1999) (Pubitemid 29048862)
128. Chester, J.D., Kennedy, W., Hall, G.D., Selby, P.J. and Knowles, M.A. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Gene Ther., 10, 172-9 (2003) (Pubitemid 36582589)
129. Kuball, J., Wen, S.F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D.C., Grace, M.J. et al. Successful adenovirusmediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol., 20, 957-65 (2002) (Pubitemid 34141838)
130. McCormick, F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin. Cancer Biol., 10, 453-9 (2000) (Pubitemid 32181915)
131. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., McDonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K. and Kyritsis, A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19, 2-12 (2000) (Pubitemid 30066345)
132. Lane, D.P. and Hupp, T.R. Drug discovery and p53. Drug Discov Today, 8, 347-55 (2003) (Pubitemid 36398162)
133. Berkson, R.G., Hollick, J.J., Westwood, N.J., Woods, J.A., Lane, D.P. and Lain, S. Pilot screening programme for small molecule activators of p53. Int. J. Cancer, 115, 701-10 (2005) (Pubitemid 40776692)
134. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L.G., Masucci, M., Pramanik, A. and Selivanova, G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med., 10, 1321-8 (2004) (Pubitemid 40022713)
135. Elder, P.A., Bell, S.M. and Knowles, M.A. Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4p16.3. Oncogene, 9, 3433-6 (1994) (Pubitemid 24359379)
136. Polascik, T.J., Cairns, P., Chang, W.Y.H., Schoenberg, M.P. and Sidransky, D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res., 55, 5396-5399 (1995)
137. Habuchi, T., Devlin, J., Elder, P.A. and Knowles, M.A. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene, 11, 1671-1674 (1995)
138. Fearon, E.R., Feinberg, A.P., Hamilton, S.H. and Vogelstein, B. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature, 318, 377-380 (1985) (Pubitemid 16198495)
139. Chang, W.Y.-H., Cairns, P., Schoenberg, M.P., Polascik, T.J. and Sidransky, D. Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res., 55, 3246-3249 (1995)
140. Natrajan, R., Louhelainen, J., Williams, S., Laye, J. and Knowles, M.A. High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res., 63, 7657-62 (2003) (Pubitemid 37466692)
141. Simon, R., Burger, H., Brinkschmidt, C., Bocker, W., Hertle, L. and Terpe, H.J. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J. Pathol., 185, 345-51 (1998) (Pubitemid 28355966)
142. Richter, J., Wagner, U., Schraml, P., Maurer, R., Alund, G., Knonagel, H., Moch, H., Mihatsch, M.J., Gasser, T.C. and Sauter, G. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res., 59, 5687-91 (1999)
143. Hovey, R.M., Chu, L., Balazs, M., DeVries, S., Moore, D., Sauter, G., Carroll, P.R. and Waldman, F.M. Genetic alterations in primary bladder cancers and their metastases. Cancer Res., 58, 3555-60 (1998) (Pubitemid 28376550)
144. Yeager, T.R., DeVries, S., Jarrard, D.F., Kao, C., Nakada, S.Y., Moon, T.D., Bruskewitz, R., Stadler, W.M., Meisner, L.F., Gilchrist, K.W. et al. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev., 12, 163-74 (1998) (Pubitemid 28060447)
145. Habuchi, T., Yoshida, O. and Knowles, M.A. A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localisation of the candidate region within a single 840kb YAC. Hum. Mol. Genet., 6, 913-919 (1997) (Pubitemid 27239077)
146. Brewster, S.F., Gingell, J.C., Browne, S. and Brown, K.W. Loss of heterozygosity on chromosome18q is associated with muscle-invasive transitional cell carcinoma of the bladder. British Journal of Cancer, 70, 697-700 (1994) (Pubitemid 24305602)
147. Catto, J.W., Azzouzi, A.R., Rehman, I., Feeley, K.M., Cross, S.S., Amira, N., Fromont, G., Sibony, M., Cussenot, O., Meuth, M. et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol., 23, 2903-10 (2005) (Pubitemid 46224108)
148. Chan, M.W., Chan, L.W., Tang, N.L., Lo, K.W., Tong, J.H., Chan, A.W., Cheung, H.Y., Wong, W.S., Chan, P.S., Lai, F.M. et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int. J. Cancer, 104, 611-6 (2003) (Pubitemid 36337261)
149. Lee, M.G., Kim, H.Y., Byun, D.S., Lee, S.J., Lee, C.H., Kim, J.I., Chang, S.G. and Chi, S.G. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res., 61, 6688-92. (2001)
150. Maruyama, R., Toyooka, S., Toyooka, K.O., Harada, K., Virmani, A.K., Zochbauer-Muller, S., Farinas, A.J., Vakar-Lopez, F., Minna, J.D., Sagalowsky, A. et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res., 61, 8659-63. (2001) (Pubitemid 34013873)
151. Chan, M.W., Chan, L.W., Tang, N.L., Tong, J.H., Lo, K.W., Lee, T.L., Cheung, H.Y., Wong, W.S., Chan, P.S., Lai, F.M. et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res, 8, 464-70 (2002) (Pubitemid 34193966)
152. Tada, Y., Wada, M., Taguchi, K., Mochida, Y., Kinugawa, N., Tsuneyoshi, M., Naito, S. and Kuwano, M. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res., 62, 4048-53 (2002) (Pubitemid 34791073)
153. Baffa, R., Gomella, L.G., Vecchione, A., Bassi, P., Mimori, K., Sedor, J., Calviello, C.M., Gardiman, M., Minimo, C., Strup, S.E. et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am. J. Pathol., 156, 419-24 (2000) (Pubitemid 30643796)
154. Iliopoulos, D., Guler, G., Han, S.Y., Johnston, D., Druck, T., McCorkell, K.A., Palazzo, J., McCue, P.A., Baffa, R. and Huebner, K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene, 24, 1625-33 (2005) (Pubitemid 40396092)
155. Vecchione, A., Sevignani, C., Giarnieri, E., Zanesi, N., Ishii, H., Cesari, R., Fong, L.Y., Gomella, L.G., Croce, C.M. and Baffa, R. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res, 10, 7607-12 (2004) (Pubitemid 39557523)
156. Marcelo, C.L. and Dunham, W.R. Retinoic acid stimulates essential fatty acid-supplemented human keratinocytes in culture. J. Invest. Dermatol., 108, 758-62 (1997) (Pubitemid 27192350)
157. Dominguez, G., Carballido, J., Silva, J., Silva, J.M., Grcia, J.M., Menendez, J., Provencio, M., Espana, P. and Bonilla, F. p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients. Clin Cancer Res, 8, 980-5. (2002) (Pubitemid 35177345)
158. Friedrich, M.G., Chandrasoma, S., Siegmund, K.D., Weisenberger, D.J., Cheng, J.C., Toma, M.I., Huland, H., Jones, P.A. and Liang, G. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer (2005)
159. Tsutsumi, M., Tsai, Y.C., Gonzalgo, M.L., Nichols, P.W. and Jones, P.A. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. Oncogene, 17, 3021-7 (1998) (Pubitemid 29012205)
160. Akao, T., Kakehi, Y., Itoh, N., Ozdemir, E., Shimizu, T., Tachibana, A., Sasaki, M.S. and Yoshida, O. A high prevalence of functional inactivation by methylation modification of p16 (ink4a)/cdkn2/mts1 gene in primary urothelial cancers. Jpn. J. Cancer Res., 88, 1078-1086 (1997) (Pubitemid 28021479)
161. Le Frere-Belda, M.A., Cappellen, D., Daher, A., Gil-Diez-de-Medina, S., Besse, F., Abbou, C.C., Thiery, J.P., Zafrani, E.S., Chopin, D.K. and Radvanyi, F. p15 (INK4b) in bladder carcinomas: decreased expression in superficial tumours. Br. J. Cancer, 85, 1515-21. (2001) (Pubitemid 34001583)
162. Kim, W.J., Kim, E.J., Jeong, P., Quan, C., Kim, J., Li, Q.L., Yang, J.O., Ito, Y. and Bae, S.C. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res., 65, 9347-54 (2005) (Pubitemid 41508002)
163. Suzuki, M., Shigematsu, H., Shames, D.S., Sunaga, N., Takahashi, T., Shivapurkar, N., Iizasa, T., Frenkel, E.P., Minna, J.D., Fujisawa, T. et al. DNA methylationassociated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br. J. Cancer, 93, 1029-1037 (2005) (Pubitemid 41548398)
164. Marsit, C.J., Karagas, M.R., Andrew, A., Liu, M., Danaee, H., Schned, A.R., Nelson, H.H. and Kelsey, K.T. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res., 65, 7081-5 (2005) (Pubitemid 41161235)